Table 5.
Ongoing clinical trials aiming at the introduction of miRNAs in clinical practice
| Clinical trial | Patient population | Intervention | Aims | Study start date |
|---|---|---|---|---|
| NCT00581750 observational | Patients with lobular carcinoma in situ | Tumor profiling | Diagnosis | October 2001 |
| NCT01231386 observational | Patients undergoing neoadjuvant or adjuvant chemotherapy and HT for locally advanced and inflammatory BC | Tumor profiling, Circulating miRNAs | Prognosis drug sensitivity | October 2014 |
| NCT01722851 observational | Newly diagnosed BC patients who are scheduled to undergo neoadjuvant chemotherapy/HT and patients who present with disease recurrence or disease progression, and who are commenced on systemic therapies (HT and/or chemotherapy) | Circulating miRNAs | Prognosis drug sensitivity | September 2013 |
| NCT02656589 observational | Patients with HER2+ advanced stage BC who were treated with herceptin | Drug sensitivity | June 2015 | |
| NCT01598285 observational | Patients suffering from metastatic BC, treated with bevacizumab | May 2012 | ||
| NCT01612871 observational | Patients with metastatic invasive BC or locally advanced BC for which treatment with tamoxifen or anti-aromatase is indicated | June 2012 |